Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;116:2165-2172
Published online before print October 22, 2007, doi: 10.1161/CIRCULATIONAHA.107.705657
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
116/19/2165    most recent
CIRCULATIONAHA.107.705657v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gomaraschi, M.
Right arrow Articles by Calabresi, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gomaraschi, M.
Right arrow Articles by Calabresi, L.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
*Genetics Home Reference
Hazardous Substances DB
*NITRIC OXIDE
Related Collections
Right arrow Lipid and lipoprotein metabolism
Right arrow Endothelium/vascular type/nitric oxide

(Circulation. 2007;116:2165-2172.)
© 2007 American Heart Association, Inc.


Vascular Medicine

Normal Vascular Function Despite Low Levels of High-Density Lipoprotein Cholesterol in Carriers of the Apolipoprotein A-IMilano Mutant

Monica Gomaraschi, PhD; Damiano Baldassarre, PhD; Mauro Amato, PhD; Sonia Eligini, PhD; Paola Conca, PhD; Cesare R. Sirtori, MD, PhD; Guido Franceschini, PhD; Laura Calabresi, PhD

From the Center E. Grossi Paoletti (M.G., D.B., S.E., P.C., C.R.S., G.F., L.C.), Department of Pharmacological Sciences, University of Milano, and the Center Cardiologico Monzino (D.B., M.A.), Istituti di Ricovero e Cura Carattere Scientifico (IRCCS), Milan, Italy.

Correspondence to Guido Franceschini, PhD, Center Grossi Paoletti, Department of Pharmacological Sciences, Via Balzaretti 9, 20133 Milano, Italy. E-mail Guido.Franceschini{at}unimi.it

Received March 27, 2007; accepted September 6, 2007.

Background— Carriers of the apolipoprotein A-IMilano (apoA-IM) mutant have very low plasma high-density lipoprotein cholesterol (HDL-C) levels but do not show any history of premature cardiovascular disease or any evidence of preclinical vascular disease. HDL is believed to prevent the development of vascular dysfunction, which may well contribute to HDL-mediated atheroprotection. Whether the low HDL level of apoA-IM carriers is associated with impaired vascular function is presently unknown.

Methods and Results— The vascular response to reactive hyperemia, assessed by measuring postischemic increase in forearm arterial compliance, and the plasma concentration of soluble cell adhesion molecules were evaluated in 21 adult apoA-IM carriers, 21 age- and gender-matched nonaffected relatives (control subjects), and 21 healthy subjects with low HDL-C (low-HDL subjects). The average plasma HDL-C and apoA-I levels of apoA-IM carriers were remarkably lower than those of control subjects and significantly lower than those of low-HDL subjects. The postischemic increase in forearm arterial compliance in the apoA-IM carriers was 2-fold greater than in low-HDL subjects and remarkably similar to that of control subjects. Plasma soluble cell adhesion molecule levels were similar in apoA-IM carriers and control subjects but were greater in low-HDL subjects. When incubated with endothelial cells, HDL isolated from apoA-IM carriers was more effective than HDL from control and low-HDL subjects in stimulating endothelial nitric oxide synthase expression and activation and in downregulating tumor necrosis factor-{alpha}–induced expression of vascular cell adhesion molecule-1.

Conclusions— Despite their very low HDL levels, apoA-IM carriers do not display typical features of impaired vascular function because of an improved activity of apoA-IM HDL in maintaining endothelial cell homeostasis.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
X.-Q. Zhao and B. G. Brown
ApoA-I(Milano)/phospholipid complex: clinical implications of dose-response studies in rabbit atherosclerosis with intravascular ultrasound and magnetic resonance imaging.
J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1110 - 1111.
[Full Text] [PDF]